Polaryx Therapeutics, Inc. Common Stock

PLYX

Biotechnology · Healthcare

Price

$2.28

-0.03 (-1.30%)

Market Cap

$113.6M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count falling — buybacks

−75.0% over 2y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 189.4M (2023) → 47.3M (2025)

Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances produ

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-101.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$6M/ year

↑ Rising (+123% vs prior year)

R&D investment increasing — building for the future

Insider Activity

53.5%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~6 months

$3M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Polaryx Therapeutics, Inc. Common Stock has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-78.7%

Weak — -78.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial